The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mullins, D. W.
Right arrow Articles by Elgert, K. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mullins, D. W.
Right arrow Articles by Elgert, K. D.
The Journal of Immunology, 1999, 162: 6811-6818.
Copyright © 1999 by The American Association of Immunologists

Paclitaxel Enhances Macrophage IL-12 Production in Tumor-Bearing Hosts Through Nitric Oxide1

David W. Mullins2, Carol J. Burger and Klaus D. Elgert3

Department of Biology, Microbiology and Immunology Section, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061

Tumor-induced macrophages (M{phi}s) mediate immunosuppression, in part, through increased production of factors that suppress T cell responsiveness and underproduction of positive regulatory cytokines. Pretreatment of tumor-bearing host (TBH) M{phi}s with the anticancer agent paclitaxel (Taxol) partially reverses tumor-induced M{phi} suppressor activity, suggesting that paclitaxel may restore TBH M{phi} production of proimmune factors. Because paclitaxel demonstrates LPS-mimetic capabilities and increased production of the LPS-induced immunostimulatory cytokine IL-12 could account for enhanced T cell responsiveness, we investigated whether paclitaxel induces M{phi} IL-12 production. Tumor growth significantly down-regulated M{phi} IL-12 p70 production through selective dysregulation of IL-12 p40 expression. LPS stimulation failed to overcome tumor-induced dysregulation of p40 expression. In contrast, paclitaxel significantly enhanced both normal host and TBH M{phi} IL-12 p70 production in vitro, although TBH M{phi} IL-12 production was lower than that of similarly treated normal host M{phi}s. Paclitaxel enhanced p40 expression in a dose-dependent manner. Through reconstituted M{phi} IL-12 expression, paclitaxel pretreatment relieved tumor-induced M{phi} suppression of T cell alloreactivity. Blocking M{phi} NO suppressed paclitaxel’s ability to induce IL-12 production. This suggests that paclitaxel-induced activities may involve a NO-mediated autocrine induction pathway. Collectively, these data demonstrate that paclitaxel restores IL-12 production in the TBH and ascribe a novel immunotherapeutic component to the pleiotropic activities of NO. Through its capacity to induce IL-12 production, paclitaxel may contribute to the correction of tumor-induced immune dysfunction.




This article has been cited by other articles:


Home page
CirculationHome page
M. A. Costa and D. I. Simon
Molecular Basis of Restenosis and Drug-Eluting Stents
Circulation, May 3, 2005; 111(17): 2257 - 2273.
[Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
M. A. P. Oliveira, G. M. A. C. Lima, M. T. Shio, P. J. M. Leenen, and I. A. Abrahamsohn
Immature macrophages derived from mouse bone marrow produce large amounts of IL-12p40 after LPS stimulation
J. Leukoc. Biol., November 1, 2003; 74(5): 857 - 867.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
D. W. Mullins, R. S. Martins, and K. D. Elgert
Tumor-Derived Cytokines Dysregulate Macrophage Interferon-{gamma} Responsiveness and Interferon Regulatory Factor-8 Expression
Experimental Biology and Medicine, March 1, 2003; 228(3): 270 - 277.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
D. M. Flanagan, C. D. Jennings, S. W. Goes, B. E. Caywood, R. Gross, A. M. Kaplan, and J. S. Bryson
Nitric oxide participates in the intestinal pathology associated with murine syngeneic graft-versus-host disease
J. Leukoc. Biol., October 1, 2002; 72(4): 762 - 768.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
N. N. Panjwani, L. Popova, and P. K. Srivastava
Heat Shock Proteins gp96 and hsp70 Activate the Release of Nitric Oxide by APCs
J. Immunol., March 15, 2002; 168(6): 2997 - 3003.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. A. Holden, Y. Lan, A. M. Pardo, J. S. Wesolowski, and S. D. Gillies
Augmentation of Antitumor Activity of an Antibody-Interleukin 2 Immunocytokine with Chemotherapeutic Agents
Clin. Cancer Res., September 1, 2001; 7(9): 2862 - 2869.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J.-P. H. Machiels, R. T. Reilly, L. A. Emens, A. M. Ercolini, R. Y. Lei, D. Weintraub, F. I. Okoye, and E. M. Jaffee
Cyclophosphamide, Doxorubicin, and Paclitaxel Enhance the Antitumor Immune Response of Granulocyte/Macrophage-Colony Stimulating Factor-secreting Whole-Cell Vaccines in HER-2/neu Tolerized Mice
Cancer Res., May 1, 2001; 61(9): 3689 - 3697.
[Abstract] [Full Text]


Home page
J. Leukoc. Biol.Home page
D. W. Mullins, R. S. Martins, C. J. Burger, and K. D. Elgert
Tumor cell-derived TGF-{beta} and IL-10 dysregulate paclitaxel-induced macrophage activation
J. Leukoc. Biol., January 1, 2001; 69(1): 129 - 137.
[Abstract] [Full Text]


Home page
J. Exp. Med.Home page
C. F. d'Ostiani, G. Del Sero, A. Bacci, C. Montagnoli, A. Spreca, A. Mencacci, P. Ricciardi-Castagnoli, and L. Romani
Dendritic Cells Discriminate between Yeasts and Hyphae of the Fungus Candida albicans: Implications for Initiation of T Helper Cell Immunity In Vitro and In Vivo
J. Exp. Med., May 8, 2000; 191(10): 1661 - 1674.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1999 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1999 by The American Association of Immunologists, Inc. All rights reserved.